Person

John C. Reed

EVP, Innovative Medicine, R&D, Johnson & Johnson

Current S&P 500 boards
0
Current roles
1
Open-market buys
$0
Open-market sales
$20.4M

Current roles

From Section 16 filings (Forms 3, 4 and 5) in the last 13 months.

Past roles

“Last filing” is the latest Form 3/4/5 for that company, an upper bound on the end date.

None on record since 2016.

Sits alongside

People who currently share a board or management team with this person.

Open-market trades

Purchases and sales reported on Form 4 at S&P 500 companies.

DateCompanyTypeSharesPriceValue
Feb 17, 2026JNJSale29,927$243.00$7.3M
Feb 17, 2026JNJSale2,283$243.00$555K
Feb 17, 2026JNJSale21,721$243.00$5.3M
Oct 17, 2025JNJSale21,721$192.71$4.2M
Jul 17, 2025JNJSale19,137$163.55$3.1M

SEC reporting-owner ID (CIK) 1181561 · all filings on EDGAR